Blue Light Photobiomodulation Therapy on Neuroischemic Patients (HERMES)
A Single-center Prospective Randomized Controlled Study on the Efficacy of Blue Light in the Therapy of Neuro-ischemic Foot Lesions in Patients With Type I or II Diabetes in a Combined Hospital /Territory Treatment Regimen.
Sponsor: Emoled
Terminated
very low enrollment rate
Other Diabetic Foot Ulcer trials with similar outcome
A NA clinical study on Diabetic Foot Ulcer, this trial is terminated or withdrawn. The trial is conducted by Emoled and has accumulated 9 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Dec 2024 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2024 — Dec 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Oct 2023 — Jul 2024 [monthly]
Recruiting NA
-
Jun 2022 — Oct 2023 [monthly]
Recruiting NA
Status: Active Not Recruiting → Recruiting
▶ Show 4 earlier versions
-
Dec 2021 — Jun 2022 [monthly]
Active Not Recruiting NA
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting NA
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting NA
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Emoled
- Ospedale San Donato
- University of Pisa
For direct contact, visit the study record on ClinicalTrials.gov .